The use of alternative treatments such as Cell and Gene Therapies (CAGT) holds great potential for bridging the gaps left by traditional treatments. These innovative CAGT clinical development programs require a suite of complex laboratory assessments to satisfy regulatory submissions and support Proof of Mechanism, Pharmacodynamic, Safety and Efficacy investigations. IQVIA Laboratories, with its global laboratory network and industry leading subject matter experts, is ideally positioned to shape, validate, and deliver those biomarker assessments.
Download our factsheet to learn more
Download Document
Related Insights
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
Labmatrix®
Tracking clinical trial samples and consents to support total sample lifecycle management
Anatomic Pathology brochure
Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services
Flow Cytometry Services
Leader in flow cytometry services for clinical trials
A Global Network to Empower Leaner Oncology Clinical Trials: Unlocking the Potential of Local Genomic Biomarker Testing in Europe
Translational Science and Innovation Laboratory (TSAIL)
Translational biomarker solutions to accelerate the adoption of assays into clinical trials though new technology evaluation and early biomarker discovery
Alzheimer’s Disease Clinical Trials
Innovative laboratory solutions to accelerate progress
Anatomic Pathology Lab Services
I-O clinical development podcast series
Pediatrics Drug Development Solutions
Download our brochure for information about our pediatric sampling capabilities
